YOUR SEARCH FOR Text 61 RESULTS
1 of Total
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Highlights (unaudited, in thousands, except per share amounts) Three Months Ended … 56 % GAAP change in fair value of acquisition-related contingent …
2 of Total
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Pharmaceuticals completed – $2.0 billion share repurchase completed, underscoring … clinical pipeline and Incyte's long-term value." Transformation of Pipeline Incyte …
3 of Total
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… in the key secondary endpoints with nominal p-values. These key secondary endpoints still … Highlights (unaudited, in thousands, except per share amounts) Three Months Ended March …
4 of Total
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates | Incyte
… reviewing our R&D efforts and focusing on high-value programs that are scientifically … Highlights (unaudited, in thousands, except per share amounts) Three Months Ended …
5 of Total
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Highlights (unaudited, in thousands, except per share amounts) Three Months Ended March 31 , … GAAP (gain) loss on change in fair value of acquisition-related contingent …
6 of Total
Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… INCB106385/INCA00186: At AACR, Incyte shared clinical and pre-clinical data from … 97,573 26% GAAP change in fair value of acquisition-related contingent …
7 of Total
Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… endpoints Conference Call and Webcast Scheduled Today at 8:00 a.m. EDT WILMINGTON, … Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today reports 2021 second quarter financial …
8 of Total
Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Highlights (unaudited, in thousands, except per share amounts) … GAAP change in fair value of acquisition-related contingent …
9 of Total
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Highlights (unaudited, in thousands, except per share amounts) Three Months Ended Six … GAAP change in fair value of acquisition-related contingent …
10 of Total
Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Highlights (unaudited, in thousands, except per share amounts) Three Months Ended September … GAAP (gain) loss on change in fair value of acquisition-related contingent …